cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1386Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEW ARTICLESПатофизиологические механизмы и генетические маркеры рестеноза после чрескожных коронарных вмешательствRestenosis pathophysiological mechanisms and genetic markers after percutaneous coronary interventionsШуваловаЮ. А.ShuvalovaYu. A.meshkov@cardio.ruМешковА. Н.MeshkovA. N.meshkov@cardio.ruКаминныйА. И.KaminnyA. I.meshkov@cardio.ruПиксинаГ. Ф.PiksinaG. F.meshkov@cardio.ruКухарчукВ. В.KukharchukV. V.meshkov@cardio.ruФГУ «Российский кардиологический научно-производственный комплекс» Росздрава, МоскваRussian Cardiology Scientific and Clinical Complex, State Federal Agency for Health and Social Development, Moscow20072010200765107114Copyright © Шувалова Ю.А., Мешков А.Н., Каминный А.И., Пиксина Г.Ф., Кухарчук В.В., 20072007Шувалова Ю.А., Мешков А.Н., Каминный А.И., Пиксина Г.Ф., Кухарчук В.В.Shuvalova Y.A., Meshkov A.N., Kaminny A.I., Piksina G.F., Kukharchuk V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1386

Рестенозирование коронарных артерий (КА) остается главным ограничением эффективности чрескожной транслюминальной коронарной ангиопластики (ЧТКА) и коронарного стентирования (КС). Цель обзора – рассмотреть механизмы патогенеза рестенозирования КА после ЧТКА и КС; проанализировать различные полиморфизмы кандидатных генов, которые могут быть вовлечены в патогенез развития рестеноза после баллонной ангиопластики (БАП) и рестеноза в стенте, как потенциальные генетические маркеры развития рестеноза после ЧТКА и КС.

Патофизиологические механизмы, генетический базис развития рестеноза в стенте и после БАП без стентирования различаются. Существуют гены, которые могут быть использованы как генетические маркеры риска развития рестеноза в стенте. С другой стороны, есть гены, которые служат генетическими маркерами риска развития рестеноза после ЧТКА. Генетическое тестирование перед выполнением ЧТКА, в ближайшем будущем позволит определять пациентов с высоким риском развития рестеноза, что вместе с разработкой новых фармакологических подходов будет способствовать снижению частоты рестенозирования КА после БАП и КС.

Coronary restenosis remains the main problem for effectiveness of percutaneous transluminal coronary angioplasty (PCA) and coronary stenting (CS). The aim of this review is to analyze pathogenetic mechanisms of coronary restenosis after PCA and CS, as well as various polymorphisms of relevant candidate genes as potential genetic markers of post‑PCA and post‑CS restenosis. Both pathophysiological mechanisms and genetic basis are different for stent restenosis and post‑PCA, stent‑free restenosis. There are genes, which could be used as genetic markers of stent restenosis risk. For PCA restenosis risk, there are genes, also used as genetic markers. Genetic testing before percutaneous coronary interventions could identify patients with high restenosis risk, that, combined with new pharmaceutical approaches, will decrease coronary restenosis rates after PCA and CS.

полиморфизмы геновчрезкожная транслюминальная баллонная ангиопластикастентирование коронарных артерийрестенозgene polymorphismspercutaneous transluminal balloon angioplastycoronary stentingrestenosisReferencesFischman DL, Leon MB, Baim DS, et al. A randomized com- parison of coronary – stene placement and balloon angioplasty in the treatment of cprpnary artery disease. Stent Restenosis Study Investigators. N Engl J Med, 1994; 331: 496–501Fischman DL, Leon MB, Baim DS, et al. A randomized com- parison of coronary – stene placement and balloon angioplasty in the treatment of cprpnary artery disease. Stent Restenosis Study Investigators. N Engl J Med, 1994; 331: 496–501Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of bal- loon – expandable – stent implantation eith balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med, 1994; 331: 489–95Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of bal- loon – expandable – stent implantation eith balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med, 1994; 331: 489–95Hoffmann R, Mintz GS. Coronary in-stent restenosis – predic- tors, treatment and prevention. Europ Heart J, 2000; 21: 1739-49Hoffmann R, Mintz GS. Coronary in-stent restenosis – predic- tors, treatment and prevention. Europ Heart J, 2000; 21: 1739-49Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. JACC, 1992; 20: 1284–93Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. JACC, 1992; 20: 1284–93Horibe H, Yamada Y, Ichihara S, et al. Genetic risk for restenosis after coronary ballon angioplasty. Aterosclerosis, 2004; 174: 181-7Horibe H, Yamada Y, Ichihara S, et al. Genetic risk for restenosis after coronary ballon angioplasty. Aterosclerosis, 2004; 174: 181-7Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation, 1996; 94: 35–43Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation, 1996; 94: 35–43Agema WRP, Jukema JW, Pimstone SN, Kastelein JJP. Genetic aspects of restenosis after percutaneous coronary interventions. Eur Heart J, 2001; 22: 2058-74Agema WRP, Jukema JW, Pimstone SN, Kastelein JJP. Genetic aspects of restenosis after percutaneous coronary interventions. Eur Heart J, 2001; 22: 2058-74DA Lane and PJ Grant. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood, 2000; 95: 1517-32DA Lane and PJ Grant. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood, 2000; 95: 1517-32Chandrasekar B, Tanguay J-F. Platele ts and restenosis. JACC, 2000; 35: 555-62Chandrasekar B, Tanguay J-F. Platele ts and restenosis. JACC, 2000; 35: 555-62Gawaz M, Neumann FJ, Ott I, et al. Changes in membrane gly- coproteins of circulating platelets after coronary stent implanta- tion. Heart. 1996; 76: 166–72Gawaz M, Neumann FJ, Ott I, et al. Changes in membrane gly- coproteins of circulating platelets after coronary stent implanta- tion. Heart. 1996; 76: 166–72Calvette JJ. On the structure and function of platelet integrin a_IIb b_3, the fibrinogen receptor. Proc Soc Exp Biol Med, 1995; 208: 346–60Calvette JJ. On the structure and function of platelet integrin a_IIb b_3, the fibrinogen receptor. Proc Soc Exp Biol Med, 1995; 208: 346–60Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation, 1999; 99: 44–52Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation, 1999; 99: 44–52Carter AM, Ossei-Gerning N, Wilson IJ, et al. Association of the platelet PlA polymorphism of glycoprotein IIb/IIIa and the fib- rinogen Bβ 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation, 1997; 96: 1424–31Carter AM, Ossei-Gerning N, Wilson IJ, et al. Association of the platelet PlA polymorphism of glycoprotein IIb/IIIa and the fib- rinogen Bβ 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation, 1997; 96: 1424–31Montalescot G, Ankri A, Vicaut E, et al. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation, 1995; 92: 31–8Montalescot G, Ankri A, Vicaut E, et al. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation, 1995; 92: 31–8Sakata K Miura F, Sugino H, et al. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associat- ed with restenosis. Am Heart J, 1996; 131: 1–6Sakata K Miura F, Sugino H, et al. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associat- ed with restenosis. Am Heart J, 1996; 131: 1–6Volzke H, Grimm R, Robinson DM, et al. Candidate genetic markers and the risk of restenosis after coronary angioplasty. Clin Sci (Lond), 2004. 106: 35–42Volzke H, Grimm R, Robinson DM, et al. Candidate genetic markers and the risk of restenosis after coronary angioplasty. Clin Sci (Lond), 2004. 106: 35–42Mamotte CD, van Bockxmeer FM, Taylor RR. Pla1/Pla2 poly- morphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty. Am J Cardiol. 1998; 82: 13–6Mamotte CD, van Bockxmeer FM, Taylor RR. Pla1/Pla2 poly- morphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty. Am J Cardiol. 1998; 82: 13–6Monraats PS, Rana JS, Zwinderman AH, et al. -455G/A poly- morphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement. Thromb Haemost, 2005; 93(3): 564-9Monraats PS, Rana JS, Zwinderman AH, et al. -455G/A poly- morphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement. Thromb Haemost, 2005; 93(3): 564-9Kastrati A, Koch W, Gawaz M, et al. PLA polymorphism of gly- coprotein IIIa and risk of adverse events after coronary stent placement. JACC, 2000; 36: 84–9Kastrati A, Koch W, Gawaz M, et al. PLA polymorphism of gly- coprotein IIIa and risk of adverse events after coronary stent placement. JACC, 2000; 36: 84–9Bottiger C, Koch W, Lahn C, et al. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. Am Heart J, 2003; 146: 855–61Bottiger C, Koch W, Lahn C, et al. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. Am Heart J, 2003; 146: 855–61Ortlepp JR, Hoffmann R, Killian A, et al. The 4G/5G promoter polymorphism of the plasninogen activator inhibitor-1 gene and late lumen loss after coronary stent placement in smoking and nonsmoking patients. Clin Cardiol, 2001; 24: 585–91Ortlepp JR, Hoffmann R, Killian A, et al. The 4G/5G promoter polymorphism of the plasninogen activator inhibitor-1 gene and late lumen loss after coronary stent placement in smoking and nonsmoking patients. Clin Cardiol, 2001; 24: 585–91von Beckerath N, Koch W, Mehilli J, et al. Glycoprotein Ia C807T polymorphism and risk of restenosis following coronary stenting. Atherosclerosis, 2001; 156: 463–8von Beckerath N, Koch W, Mehilli J, et al. Glycoprotein Ia C807T polymorphism and risk of restenosis following coronary stenting. Atherosclerosis, 2001; 156: 463–8Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J, 2004; 25: 1679-87Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J, 2004; 25: 1679-87Tashiro H, Shimokawa H, Sadamatsu K, et al. Role of cytokines in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty. Coron Artery Dis, 2001; 12: 107–13Tashiro H, Shimokawa H, Sadamatsu K, et al. Role of cytokines in the pathogenesis of restenosis after percutaneous transluminal coronary angioplasty. Coron Artery Dis, 2001; 12: 107–13Francis SE, Camp NJ, Burton AJ, et al. Interleukin 1 receptor antagonist gene polymorphism and restenosis after coronary angioplasty. Heart, 2001; 86: 336–40Francis SE, Camp NJ, Burton AJ, et al. Interleukin 1 receptor antagonist gene polymorphism and restenosis after coronary angioplasty. Heart, 2001; 86: 336–40Kastrati A, Koch W, Berger PB, et al. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. JACC, 2000; 36: 2168–73Kastrati A, Koch W, Berger PB, et al. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. JACC, 2000; 36: 2168–73Gomma AH, Elrayess MA, Knight CJ, et al. The endothelial nitric oxide synthase (Glu298Asp and -786T>C) gene polymorphism are associated with coronary in-stent restenosis. Eur Heart J, 2002; 23: 1955–62Gomma AH, Elrayess MA, Knight CJ, et al. The endothelial nitric oxide synthase (Glu298Asp and -786T>C) gene polymorphism are associated with coronary in-stent restenosis. Eur Heart J, 2002; 23: 1955–62Koch W, Tiroch K, von Beckerath N, et al. Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. Cytokine, 2003; 24: 161–71Koch W, Tiroch K, von Beckerath N, et al. Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. Cytokine, 2003; 24: 161–71Humphries S, Bauters C, Meirhaeghe A, et al. The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. Eur Heart J, 2002;23: 721–5Humphries S, Bauters C, Meirhaeghe A, et al. The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. Eur Heart J, 2002;23: 721–5Chiou KR, Chung SL, Charng MJ. 5A/6A polymorphism of the stromelysin-1 gene and angiographic restenosis after coronary artery stenting. J Chin Med Assoc, 2005; 68(11): 506-12Chiou KR, Chung SL, Charng MJ. 5A/6A polymorphism of the stromelysin-1 gene and angiographic restenosis after coronary artery stenting. J Chin Med Assoc, 2005; 68(11): 506-12Hoppmann P, Koch W, Schomig A, Kastrati A. The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percuta-neous coronary interventions Eur Heart J, 2004; 25: 335-41Hoppmann P, Koch W, Schomig A, Kastrati A. The 5A/6A polymorphism of the stromelysin-1 gene and restenosis after percuta-neous coronary interventions Eur Heart J, 2004; 25: 335-41Itoh H, Mukoyama M, Pratt RE, et al. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest, 1993; 91: 2268–74Itoh H, Mukoyama M, Pratt RE, et al. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest, 1993; 91: 2268–74Oike Y, Hata A, Ogata Y, et al. Angiotensin converting enzyme as a genetic risk factor for coronary artery spasm. Implication in the pathogenesis of myocardial infarction. J Clin Invest, 1995; 96: 2975–9Oike Y, Hata A, Ogata Y, et al. Angiotensin converting enzyme as a genetic risk factor for coronary artery spasm. Implication in the pathogenesis of myocardial infarction. J Clin Invest, 1995; 96: 2975–9Prisco D, Fatini C, Battaglini B, et al. Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor-1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients. Int J Clin Lab Res, 2000; 30: 179–85Prisco D, Fatini C, Battaglini B, et al. Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor-1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients. Int J Clin Lab Res, 2000; 30: 179–85Ding`YA, MacIntyre DE, Kenyon CJ, et al. Potentiation of adrenaline-induced platelet aggregation by angiotensin II. Thromb Haemost, 1985: 54: 717–20Ding`YA, MacIntyre DE, Kenyon CJ, et al. Potentiation of adrenaline-induced platelet aggregation by angiotensin II. Thromb Haemost, 1985: 54: 717–20Rakugi H, Jacob HJ, Krieger JE, et al. Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation, 1993; 87: 283-90Rakugi H, Jacob HJ, Krieger JE, et al. Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation, 1993; 87: 283-90Samani NJ, Thompson JR, O`Toole L, et al. A meta-analysis of the association of the deletion allele of the angiotensin converting enzyme gene with myocardial infarction. Circulation, 1996; 94: 708–12Samani NJ, Thompson JR, O`Toole L, et al. A meta-analysis of the association of the deletion allele of the angiotensin converting enzyme gene with myocardial infarction. Circulation, 1996; 94: 708–12Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin converting enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J med, 1995; 332: 706–11Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin converting enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J med, 1995; 332: 706–11Volzke H, Hertwig S, Rettig R, Motz W. The angiotensinogen gene 235T variant is associated with an increased risk of restenosis after percutaneous transluminal coronary angioplasty. Clin Sci (Lond), 2000; 99(1): 19-25Volzke H, Hertwig S, Rettig R, Motz W. The angiotensinogen gene 235T variant is associated with an increased risk of restenosis after percutaneous transluminal coronary angioplasty. Clin Sci (Lond), 2000; 99(1): 19-25Hertwig S, Volzke H, Robinson DM, et al. Angiotensinogen M235T polymorphism and recurrent restenosis after repeated percutaneous transluminal coronary angioplasty. Clin Sci, 2002; 103: 101–6Hertwig S, Volzke H, Robinson DM, et al. Angiotensinogen M235T polymorphism and recurrent restenosis after repeated percutaneous transluminal coronary angioplasty. Clin Sci, 2002; 103: 101–6Ribichini F, Ferrero V, Matullo G, et al. Association study of the I/D polymorphism and plasma angiotensin-converting enzyme (ACE) as risk factors for stent restenosis. Clin Sci (Lond), 2004; 107(4): 381-9Ribichini F, Ferrero V, Matullo G, et al. Association study of the I/D polymorphism and plasma angiotensin-converting enzyme (ACE) as risk factors for stent restenosis. Clin Sci (Lond), 2004; 107(4): 381-9Ryu SK, Cho EY, Park HY, Im EK, et al. Renin-angiotensin-aldosterone system (RAAS) gene polymorphism as a risk factor of coronary in-stent restenosis. Yonsei Med J, 2002; 43(4): 461-72Ryu SK, Cho EY, Park HY, Im EK, et al. Renin-angiotensin-aldosterone system (RAAS) gene polymorphism as a risk factor of coronary in-stent restenosis. Yonsei Med J, 2002; 43(4): 461-72Wijpkema JS, van Haelst PL, Monraats PS, et al. Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. Pharmacogenet Genomics, 2006; 16(5): 331-7Wijpkema JS, van Haelst PL, Monraats PS, et al. Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. Pharmacogenet Genomics, 2006; 16(5): 331-7Le Tourneau T, Van Belle E, Corseaux D, et al. Role of nitric oxide in restenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit: effects on neointimal hyperplasia and vascular remodeling. JACC, 1999; 33: 876–82Le Tourneau T, Van Belle E, Corseaux D, et al. Role of nitric oxide in restenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit: effects on neointimal hyperplasia and vascular remodeling. JACC, 1999; 33: 876–82Hibi K, Ishigami T, Tamura K, et al. endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension, 1998; 32: 521–6Hibi K, Ishigami T, Tamura K, et al. endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension, 1998; 32: 521–6Suzuki T, Okumura K, Sone T, et al. The Glu298Asp polymorphism in endothelial nitric oxide synthase gene is associated with coronary in-stent restenosis. Int J Cardiol, 2002; 6: 71–6Suzuki T, Okumura K, Sone T, et al. The Glu298Asp polymorphism in endothelial nitric oxide synthase gene is associated with coronary in-stent restenosis. Int J Cardiol, 2002; 6: 71–6Chung SL, Chiou KR, Charng MJ. 677TT polymorphism of methylenetetrahydrofolate reductase in combination with low serum vitamin B (12) is associated with coronary in-stent restenosis. Catheter Cardiovasc Interv. 2006 67 (3): 349-55Chung SL, Chiou KR, Charng MJ. 677TT polymorphism of methylenetetrahydrofolate reductase in combination with low serum vitamin B (12) is associated with coronary in-stent restenosis. Catheter Cardiovasc Interv. 2006 67 (3): 349-55Toshisuke Morita. Heme Oxygenase and Atherosclerosis. Arterioscler. Thromb Vasc Biol, 2005; 25: 1786 – 95Toshisuke Morita. Heme Oxygenase and Atherosclerosis. Arterioscler. Thromb Vasc Biol, 2005; 25: 1786 – 95Exner M, Schillinger M, Minar E, et al. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther, 2001; 8: 433–40Exner M, Schillinger M, Minar E, et al. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther, 2001; 8: 433–40Chen YH, Chau LY, Lin MW, et al. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with angiographic restenosis after coronary stenting. Eur Heart J, 2004; 25: 39–47Chen YH, Chau LY, Lin MW, et al. Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with angiographic restenosis after coronary stenting. Eur Heart J, 2004; 25: 39–47Gulesserian T, Wenzel C, Endler G, et al. Clinical Restenosis after Coronary Stent Implantation Is Associated with the Heme Oxygenase-1 Gene Promoter Polymorphism and the Heme Oxygenase-1 -99G/C Variant. Clin Chem, 2005; 51, (9): 1661-5Gulesserian T, Wenzel C, Endler G, et al. Clinical Restenosis after Coronary Stent Implantation Is Associated with the Heme Oxygenase-1 Gene Promoter Polymorphism and the Heme Oxygenase-1 -99G/C Variant. Clin Chem, 2005; 51, (9): 1661-5Li P, Gomma MA, Palmen J, Hawe E, et al. The microsatellite polymorphism of heme oxygenase-1 is associated with baseline plasma IL-6 level but not with restenosis after coronary in-stenting. Chin Med J, 2005; 118(18): 1525 – 32Li P, Gomma MA, Palmen J, Hawe E, et al. The microsatellite polymorphism of heme oxygenase-1 is associated with baseline plasma IL-6 level but not with restenosis after coronary in-stenting. Chin Med J, 2005; 118(18): 1525 – 32Shi Y, Niculescu К, Wang D, et al. Increased NAD (P) H Oxidase end Reactive Oxygen Species in Coronary Arteries After Balloon Injury. Arterioscler. Thromb. Vasc. Biol., 2001; 21: 739- 45Shi Y, Niculescu К, Wang D, et al. Increased NAD (P) H Oxidase end Reactive Oxygen Species in Coronary Arteries After Balloon Injury. Arterioscler. Thromb. Vasc. Biol., 2001; 21: 739- 45Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett, 1991; 286: 152 – 4Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett, 1991; 286: 152 – 4Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary artery disease. Arterioscler Thromb Vasc Biol, 1997; 17: 1067 – 73Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary artery disease. Arterioscler Thromb Vasc Biol, 1997; 17: 1067 – 73

The authors declare that there are no conflicts of interest present.